目次
						
	Table of Contents
	I. Introduction
	II. Major Product Development Opportunities
	III. Design Criteria for Decentralized Testing Products
	IV. Alternative Market Penetration Strategies
	
	A. InternalDevelopment
	B. Collaborative Arrangements
	C. University Contracts
	D. Distribution Strategies for Decentralized Testing Markets
	V. Potential Market Entry Barriers and Risks
	
	A. Market Maturity
	B. Cost Containment
	C. Competition
	D. Technological Edge and Limitations
	E. Patent Protection
	F. Regulatory Constraints
	G. Decentralized Testing Market Challenges
	VI. Worldwide Market and Technology Overview
	
	A. Selected Tests Clinical Significance and Diagnostic Procedures
	 1. Albumin
	 2. Alkaline Phosphatase
	 3. ALT/SGPT
	 4. Ammonia
	 5. Amylase
	 6. AST/SGOT
	 7. Bilirubin, Total
	 8. Blood Gases
	 9. Blood Urea Nitrogen (BUN)
	 10. BNP
	 11. Calcium
	 12. Cardio CRP
	 13. Cholesterol
	 14. Cholinesterase
	 15. CRP
	 16. Creatinine
	 17. Electrolytes
	  a. Carbon Dioxide/Bicarbonate
	  b. Chloride
	  c. Potassium
	  d. Sodium
	 18. Ferritin
	 19. Fructosamine
	 20. Gamma-Glutamyl Transpeptidase (GGT)
	 21. Glucose
	 22. High Density Lipoprotein (HDL)
	 23. Homocysteine
	 24. hs-CRP
	 25. Iron
	 26. Lactate Dehydrogenase (LDH)
	 27. Magnesium
	 28. NT-proBNP
	 29. Phosphorus
	 30. Protein
	 31. ST2
	 32. Triglycerides
	 33. Uric Acid
	 34. Troponin
	B. Clinical Chemistry Instrumentation Review: Operating
	Characteristics and Features of High-, Medium-, and Low-volume/POC analyzers
	C. Major Clinical Chemistry Technologies and Their Potential Applications
	 1. Monoclonal and Polyclonal Antibodies
	 2. Immunoassays
	 3. Tandem Mass Spec
	 4. IT and Automation
	 5. Dry Chemistry
	 6. Biosensors
	VII. Country Analyses
	
	Albania, Algeria, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New
	Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
	VIII. Competitive Assessments
	
	Abbott
	Agilent Technologies
	Beckman Coulter/Danaher
	bioMerieux
	Bio-Rad
	DiaSorin
	Eiken Chemical
	Fujirebio
	Grifols
	Instrumentation Laboratory/Werfen
	Kyowa Medex
	Ortho-Clinical Diagnostics
	PerkinElmer
	Quest Diagnostics
	Roche
	Siemens Healthineers
	Sysmex
	Thermo Fisher
	Tosoh
	Wako